Computational Biology Co-op
Ascidian Therapeutics
Computational Biology Co-op
Ascidian Therapeutics
RNA exon editing for gene therapies
Co-Op, Computational Biology
Ascidian Therapeutics is a rapidly growing Boston-based biotech startup that uses a unique molecular technology, RNA Exon Editing, to unlock gene therapy. Gene therapy is entering an exciting new era, and our approach overcomes limitations that previous technologies could not. Our goal is to revolutionize RNA based gene therapy to enable treatment for millions of patients worldwide.
Your role on the team:
Ascidian Therapeutics is seeking a Co-Op/Intern with an interest in computational biology to join our team. The Co-Op will work with an experienced scientific mentor to analyze next-generation sequencing data and contribute to the computational design of RNA drug candidates. The candidate must be creative, enthusiastic, detail-oriented, have excellent communication skills, and be willing to work in a dynamic entrepreneurial environment.
General Requirements:
Additional skills/experience beneficial, but not required:
Computational biology software tools & aligners (e.g. Samtools , BWA , MiniMap , )Molecular Biology knowledge with a focus on RNA processing & expression
Responsibilities:
RNA exon editing for gene therapies
Ascidian Therapeutics focuses on RNA exon editing to treat diseases. It develops technologies that edit RNA transcripts after they are made from DNA, enabling precise changes while keeping natural gene expression patterns. This approach aims to produce full-length, functional proteins and offer durable therapeutic effects without direct DNA editing or gene replacement. The company monetizes by licensing its RNA exon editing technology to healthcare providers and research institutions and may also participate in development and sale of therapies based on its platform. Compared with competitors, it emphasizes transcriptome re-engineering in human cells to achieve steady gene expression without altering the genome, reducing certain genetic risks while maintaining normal regulatory control. The overall goal is to translate RNA exon editing into accessible therapies for patients by partnering for licensing and therapy development.
Explore more opportunities at Ascidian Therapeutics